CAS 1414943-88-6

1,3,5-Triazin-2-amine, 4-(4-fluoro-2-methoxyphenyl)-N-[3-[(S-methylsulfonimidoyl)methyl]phenyl]-

CAS : 1414943-88-6

Formule : C₁₈H₁₈FN₅O₂S

Degré de pureté : 98%

Masse moléculaire : 387.4312

Ref: IN-DA001GHG

Atuveciclib Racemate

CAS : 1414943-88-6

Atuveciclib Racemate

Degré de pureté : ≥95%

Masse moléculaire : 387.43g/mol

Ref: 54-BUP02406

Atuveciclib

CAS : 1414943-88-6

Atuveciclib Racemate is an oral CDK9 inhibitor with a 13 nM IC50, targeting P-TEFb/CDK9 selectively.

Formule : C₁₈H₁₈FN₅O₂S

Degré de pureté : 98.8%

Couleur et forme : Solid

Masse moléculaire : 387.43

Ref: TM-T10464L

Atuveciclib, racemate

CAS : 1414943-88-6

Degré de pureté : 98%

Masse moléculaire : 387.117

Ref: 10-F840720

Atuveciclib (BAY-1143572)

CAS : 1414943-88-6

Atuveciclib is a selective inhibitor of CDK4 and CDK6 that has been shown to inhibit the growth of cancer cells in vitro. It was also shown to be effective in vivo, reducing the size of tumors in mice with bowel disease. Atuveciclib has been shown to inhibit lymphoproliferative disorders by targeting the mcl-1 protein, which is essential for cell survival. This drug inhibits the production of inflammatory cytokines such as IL-2, IL-3 and erythropoietin, which are responsible for the development of lymphoproliferative disorders. Atuveciclib has a short detection time and pharmacokinetic properties that enable it to be administered intravenously or orally. It also shows selectivity for kinases over other proteins, making it an attractive potential treatment for inflammatory bowel disease or cancer.

Formule : C₁₈H₁₈FN₅O₂S

Degré de pureté : Min. 95%

Masse moléculaire : 387.43 g/mol

Ref: 3D-PGC94388